134 related articles for article (PubMed ID: 10389653)
81. Viral dynamics in hepatitis B virus infection.
Nowak MA; Bonhoeffer S; Hill AM; Boehme R; Thomas HC; McDade H
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4398-402. PubMed ID: 8633078
[TBL] [Abstract][Full Text] [Related]
82. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
83. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
[TBL] [Abstract][Full Text] [Related]
84. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.
Parvez MK; Sehgal D; Sarin SK; Basir SF; Jameel S
World J Gastroenterol; 2006 May; 12(19):3006-14. PubMed ID: 16718779
[TBL] [Abstract][Full Text] [Related]
85. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
Da Silva LC; Pinho JR; Sitnik R; Da Fonseca LE; Carrilho FJ
J Gastroenterol; 2001 Jul; 36(7):476-85. PubMed ID: 11480792
[TBL] [Abstract][Full Text] [Related]
86. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
Yeo W; Steinberg JL; Tam JS; Chan PK; Leung NW; Lam KC; Mok TS; Johnson PJ
J Med Virol; 1999 Nov; 59(3):263-9. PubMed ID: 10502254
[TBL] [Abstract][Full Text] [Related]
87. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
88. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
89. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA.
Morrissey DV; Lee PA; Johnson DA; Overly SL; McSwiggen JA; Beigelman L; Mokler VR; Maloney L; Vargeese C; Bowman K; O'Brien JT; Shaffer CS; Conrad A; Schmid P; Morrey JD; Macejak DG; Pavco PA; Blatt LM
J Viral Hepat; 2002 Nov; 9(6):411-8. PubMed ID: 12431202
[TBL] [Abstract][Full Text] [Related]
90. Bortezomib inhibits hepatitis B virus replication in transgenic mice.
Bandi P; Garcia ML; Booth CJ; Chisari FV; Robek MD
Antimicrob Agents Chemother; 2010 Feb; 54(2):749-56. PubMed ID: 19949053
[TBL] [Abstract][Full Text] [Related]
91. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
Gallay P; Ure D; Bobardt M; Chatterji U; Ou J; Trepanier D; Foster R
PLoS One; 2019; 14(6):e0217433. PubMed ID: 31181107
[TBL] [Abstract][Full Text] [Related]
92. Anti-HBV activity of retinoid drugs in vitro versus in vivo.
Birkus G; Snyder C; Jordan R; Kobayashi T; Dick R; Puscau V; Li L; Ramirez R; Willkom M; Morikawa Y; Delaney Iv WE; Schmitz U
Antiviral Res; 2019 Sep; 169():104538. PubMed ID: 31226346
[TBL] [Abstract][Full Text] [Related]
93. [Research on HBV DNA inhibition of plasmid acute infection mouse with betulinic acid].
Qiao B; Gao YQ; Li M; Wu SF; Zheng C; Jin SG; Wu HC; Yu Z; Sun XH
Zhongguo Zhong Yao Za Zhi; 2014 Mar; 39(6):1097-100. PubMed ID: 24956858
[TBL] [Abstract][Full Text] [Related]
94. Inhibition of intrahepatic hepatitis B virus replication by antiviral drugs in a novel transgenic mouse model.
Nagahata T; Araki K; Yamamura K; Matsubara K
Antimicrob Agents Chemother; 1992 Sep; 36(9):2042-5. PubMed ID: 1416898
[TBL] [Abstract][Full Text] [Related]
95. Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice.
Long KR; Lomonosova E; Li Q; Ponzar NL; Villa JA; Touchette E; Rapp S; Liley RM; Murelli RP; Grigoryan A; Buller RM; Wilson L; Bial J; Sagartz JE; Tavis JE
Antiviral Res; 2018 Jan; 149():41-47. PubMed ID: 29129708
[TBL] [Abstract][Full Text] [Related]
96. Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice.
Morrey JD; Motter NE; Taro B; Lay M; Fairman J
Antiviral Res; 2008 Jul; 79(1):71-9. PubMed ID: 18358544
[TBL] [Abstract][Full Text] [Related]
97. Inhibitory effect of emodin and Astragalus polysaccharide on the replication of HBV.
Dang SS; Jia XL; Song P; Cheng YA; Zhang X; Sun MZ; Liu EQ
World J Gastroenterol; 2009 Dec; 15(45):5669-73. PubMed ID: 19960563
[TBL] [Abstract][Full Text] [Related]
98. Effect of dipterinyl calcium pentahydrate on hepatitis B virus replication in transgenic mice.
Moheno P; Morrey J; Fuchs D
J Transl Med; 2010 Mar; 8():32. PubMed ID: 20356392
[TBL] [Abstract][Full Text] [Related]
99. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice.
Wang W; Smith N; Makarov E; Sun Y; Gebhart CL; Ganesan M; Osna NA; Gendelman HE; Edagwa BJ; Poluektova LY
Nanomedicine; 2020 Aug; 28():102185. PubMed ID: 32217146
[TBL] [Abstract][Full Text] [Related]
100. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.
Weber O; Schlemmer KH; Hartmann E; Hagelschuer I; Paessens A; Graef E; Deres K; Goldmann S; Niewoehner U; Stoltefuss J; Haebich D; Ruebsamen-Waigmann H; Wohlfeil S
Antiviral Res; 2002 May; 54(2):69-78. PubMed ID: 12062392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
